Splet13. avg. 2024 · Background In patients who are expected to achieve axillary pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC), omission of axillary lymph node (LN) dissection could prevent morbidity and complications. Purpose To develop a clinical model to predict residual axillary LN metastasis in patients with clinically node … Splet23. mar. 2024 · Almost all patients received postoperative adjuvant therapy, including hormone therapy, chemotherapy, and target therapy, according to their clinicopathological factors. Analysis of estrogen receptor, progesterone receptor, HER2 expression and the definition of pCR were described below.
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted …
SpletTriple-negative breast cancer (TNBC) is a heterogeneous disease with varying responses to neoadjuvant chemotherapy (NAC). The identification of biomarkers to predict NAC response and inform personalized treatment strategies is essential. In this study, we conducted large-scale gene expression meta-analyses to identify genes associated with … SpletPred 1 dnevom · Interestingly, 4 patients, or 17.4% of the 23 patients [enrolled in the study], had a pathologic complete response [pCR] after 3 cycles of neoadjuvant chemoimmunotherapy. car accessories for seniors
Pathological complete response to neoadjuvant - LWW
Splet15. feb. 2024 · Primary analysis of NRG-BR005, a phase II trial assessing accuracy of tumor bed biopsies in predicting pathologic complete response (pCR) in patients with clinical/radiological complete response after neoadjuvant chemotherapy (NCT) to explore the feasibility of breast-conserving treatment without surgery [abstract]. Splet05. apr. 2024 · Phase II, single-arm, open-label single center study that assess clinical feasibility and safety of 3 cycles neoadjuvant Toripalimab plus chemotherapy in rare mutations stage IIB-IIIB NSCLC followed by optional adjuvant treatment upon investigators' decisions. 30 eligible patients will be enrolled and 3 cycles of Toripalimab 240mg ... SpletIn the absence of identified therapeutic targets, chemotherapy is the main systemic treatment option for triple-negative breast cancer (TNBC). The achievement of a … brk sc9120a no battery